Telix Pharmaceuticals (ASX: TLX) orders four IBA cyclotrons to build in-house isotope production at RLS radiopharmacy network

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Melbourne-based precision oncology company, has contracted Ion Beam Applications S.A. (EURONEXT: IBAB) for an initial order of four Cyclone KIUBE 180 cyclotrons destined for select RLS Radiopharmacies sites across the United States. The agreement, announced on 20 March 2026, represents a concrete next step in Telix’s strategy to internalise isotope production across its nationwide radiopharmacy network following the US$230 million acquisition of RLS that closed in January 2025. Each cyclotron will be paired with the QUANTM Irradiation System developed by ARTMS, the Canadian targetry specialist Telix acquired in March 2024 for US$42.5 million, enabling cGMP-compliant production of critical medical isotopes at scale. With TLX shares trading at approximately A$12.95 on the ASX today, up sharply from a 52-week low of A$8.26 but still well below a 52-week high of A$29.72, the market context underscores how much execution this strategy still requires to close the valuation gap.

Why is Telix deploying IBA cyclotrons at RLS Radiopharmacies sites rather than sourcing isotopes from external suppliers?

The logic behind the IBA contract is straightforward even if the execution is not. Radiopharmaceuticals are inherently perishable; isotopes with short physical half-lives must be produced close to the point of clinical use to arrive with meaningful activity. Sourcing critical radio-metals like gallium-68, zirconium-89, technetium-99m, and copper-64 from third-party suppliers introduces scheduling risk, delivery variability, and dependency on a vendor network that is itself straining under rising global demand. By installing cyclotron capacity directly inside its own RLS radiopharmacy facilities, Telix can produce these isotopes on-demand, reduce the cost-per-dose over time as volumes ramp, and insulate its commercial operations from supply chain disruptions that have periodically affected the wider radiopharmaceutical sector.

The RLS network gives Telix the platform to make this work at meaningful scale. RLS operates over 30 radiopharmacies across major U.S. metropolitan areas, accredited by The Joint Commission and compliant with USP 797, USP 825, and ISO 14644-1 clean room standards. The acquisition brought more than 100,000 square feet of licensed expansion space specifically identified for production scale-up. Installing cyclotrons in select sites rather than all sites at once reflects a phased deployment approach, allowing Telix to validate the manufacturing model before committing the capital to a full network rollout. That discipline matters given that Telix reported FY2025 revenue of US$803.8 million but still recorded a small pre-tax loss of US$5.3 million, with year-end cash of US$141.9 million after US$246.4 million of strategic acquisitions.

How does the ARTMS QUANTM Irradiation System change the economics of in-house cyclotron-based isotope production for Telix?

The ARTMS QUANTM Irradiation System is the technical centrepiece of this deal and arguably the reason Telix selected IBA as the hardware partner rather than a competitor. ARTMS developed a targetry platform that integrates directly with commercial cyclotrons to enable efficient, high-yield production of multiple radio-metals without requiring separate, bespoke irradiation infrastructure for each isotope. When paired with IBA’s Cyclone KIUBE 180, which the press release describes as chosen for its high-current capacity, industrial reliability, and capacity for future upgrades, the combined system creates a modular production line that can pivot across gallium-68, zirconium-89, technetium-99m, and copper-64 depending on clinical demand at each site.

That flexibility is economically significant. Radiopharmacies that produce a single isotope via a dedicated targetry arrangement face stranded capacity whenever demand patterns shift. A system capable of switching production across four high-demand isotopes reduces the utilisation risk on each capital asset. For Telix, whose commercial revenue is currently anchored by Illuccix (gallium-68 gozetotide) for prostate cancer imaging, the ability to produce gallium-68 in-house at RLS sites addresses both cost structure and supply reliability simultaneously. The addition of zirconium-89 and copper-64 capacity points toward Telix’s ambition to support its broader therapeutic pipeline and potentially supply third-party partners through Telix Manufacturing Solutions, which would open a revenue line beyond the company’s own drug portfolio.

What does the Cyclone KIUBE 180 order signal about IBA’s commercial momentum in the radiopharmaceutical production market in 2026?

For Ion Beam Applications, the Telix contract is a meaningful commercial win for its RadioPharma Solutions division at a time when the parent company’s stock has been under pressure. IBAB shares were trading around EUR 11.56 to EUR 11.70 as of today, near the lower end of a 52-week range that spans EUR 9.40 to EUR 15.90, and the stock has declined roughly 3 percent over the past month and around 3 percent over the prior year. IBA’s annual results are due on 27 March 2026, which means this contract announcement lands just days before investors get a full picture of how the radiopharmaceuticals division is performing relative to the larger proton therapy segment that historically drives the bulk of IBA’s revenue.

The Telix deal reinforces a theme IBA has been actively building: the Cyclone KIUBE platform as the preferred hardware for pharmaceutical-grade, high-throughput isotope production in a market undergoing rapid demand expansion. The three analysts covering IBAB have an average 12-month price target of approximately EUR 16.67, implying around 40 percent upside from current levels, which suggests the market has not fully priced in what a sustained run of radiopharmaceutical production contracts could mean for IBA’s earnings trajectory. Contracts of this nature carry recurring service and maintenance revenue beyond the initial hardware sale, which improves the long-term revenue visibility for IBA RadioPharma Solutions.

How does Telix’s vertically integrated U.S. manufacturing strategy compare with what competitors in radiopharmaceuticals are building?

The radiopharmaceutical sector is experiencing a structural shift as pharmaceutical companies that historically relied on external isotope suppliers and contract radiopharmacies are moving to internalise production. Eli Lilly’s acquisition of Point Biopharma in 2023 and Bristol Myers Squibb’s acquisition of RayzeBio in early 2024 both included significant manufacturing infrastructure components. Novartis has been investing in its radioligand therapy production network for several years, giving it a substantial head start in theranostics manufacturing scale. What distinguishes Telix’s approach is the combination of a nationwide distribution network through RLS, proprietary cyclotron targetry through ARTMS, and now a hardware partnership with IBA, all integrated under Telix Manufacturing Solutions as a standalone business unit that can serve both internal and external customers.

The risk in this approach is execution complexity. Cyclotron installations in radiopharmacy environments require regulatory approvals, radiation safety infrastructure, qualified operating personnel, and ongoing quality management systems to maintain cGMP compliance. Deploying this across multiple sites simultaneously, even in a phased manner starting with four machines, is operationally demanding for a company still scaling its commercial infrastructure. Telix has guided FY2026 revenue of US$950 to US$970 million alongside US$200 to US$240 million in pipeline research and development spend, which leaves limited margin for manufacturing integration to underperform on schedule or budget.

What are the regulatory and supply chain risks in deploying cyclotron production of gallium-68 and technetium-99m at distributed U.S. sites?

Gallium-68 production via cyclotron has been an active area of regulatory attention from the U.S. Food and Drug Administration. Cyclotron-produced gallium-68 operates under a different regulatory pathway than generator-produced material, requiring site-specific approvals and cGMP validation that can extend project timelines. Technetium-99m, the world’s most widely used medical isotope, has historically been produced via nuclear reactors using molybdenum-99 as a parent material; shifting to cyclotron production represents a meaningful change in the production paradigm for many clinical sites and may require additional regulatory engagement before cyclotron-produced technetium-99m can be used in routine clinical practice at each RLS facility.

These regulatory considerations are not deal-breakers, but they are timing variables that could affect how quickly each installed cyclotron generates productive output. Telix’s description of the four isotopes as initial targets suggests the company is approaching the deployment pragmatically, starting with the regulatory pathways it understands best and expanding the production menu over time. The ARTMS platform’s track record in multi-isotope production at partner sites internationally provides some evidence that the technical model is sound, but the commercial and regulatory execution at scale across a distributed U.S. network is genuinely new territory.

How does today’s TLX stock position reflect investor confidence in Telix’s capital-intensive manufacturing buildout and FY2026 revenue guidance?

TLX shares on the ASX have recovered notably in recent weeks, trading at approximately A$12.95 today after a previous close of A$12.41, a gain of around 4.3 percent on the day of the announcement. The one-month performance has been even more striking, with the stock rising approximately 46 percent over that period according to available trading data. That recovery matters as context: Telix spent most of early 2026 considerably below where it stands today, weighed down by a 52-week high of A$29.72 that the current price remains sharply below. Fourteen analysts covering the stock recommend buying it, with an average 12-month price target of approximately A$22.92, implying around 77 percent upside from current levels. The bull case rests almost entirely on execution: delivering against the FY2026 revenue guidance, advancing the therapeutic pipeline including the Phase 3 TLX591 prostate cancer therapy, and demonstrating that the manufacturing infrastructure investments like this IBA cyclotron order translate into margin improvement rather than simply higher capital expenditure.

The bear case is the mirror image: Telix is a company generating meaningful revenue but not yet consistent profit, investing heavily in manufacturing, pipeline, and infrastructure simultaneously while guiding aggressively for top-line growth. The RLS integration alone cost US$230 million. The ARTMS acquisition added US$42.5 million. Now four cyclotron systems, each a substantial capital item, are being procured at standard IBA commercial conditions. The cumulative capital deployment is significant for a company at Telix’s current scale, and the payback horizon on manufacturing infrastructure is measured in years, not quarters. Whether the market rewards that investment discipline or punishes it for diluting near-term earnings will depend largely on whether Telix can demonstrate that the RLS network and in-house production capacity are contributing meaningfully to revenue and margin by end of FY2026.

Key takeaways: what the Telix-IBA cyclotron deal means for radiopharmaceutical manufacturing, supply chains, and investor strategy

• Telix Pharmaceuticals has ordered four IBA Cyclone KIUBE 180 cyclotrons for installation at select RLS Radiopharmacies sites in the U.S., marking the first concrete hardware deployment in its vertically integrated manufacturing strategy.
• Each cyclotron will be paired with ARTMS’s QUANTM Irradiation System, enabling in-house cGMP production of gallium-68, zirconium-89, technetium-99m, and copper-64, reducing dependence on external isotope suppliers.
• The deal extends Telix’s capital deployment trajectory following the US$230 million RLS acquisition (January 2025) and the US$42.5 million ARTMS acquisition (March 2024), raising the stakes on execution for a company not yet consistently profitable.
• TLX shares trade at approximately A$12.95 today, around 57 percent below the 52-week high of A$29.72, with 14 analysts rating it a buy and an average price target of A$22.92, making manufacturing execution the central variable for re-rating.
• For IBA (EURONEXT: IBAB), the contract is a meaningful RadioPharma Solutions win ahead of its 27 March 2026 annual results, and supports a long-term revenue visibility narrative as cyclotron contracts carry recurring service and maintenance value beyond initial hardware sales.
• IBAB trades at approximately EUR 11.56 to 11.70, near the lower half of its 52-week range of EUR 9.40 to EUR 15.90, with analyst consensus pointing to roughly 40 percent upside and annual results due within days of this announcement.
• Telix’s approach of pairing IBA hardware with ARTMS proprietary targetry creates a differentiated multi-isotope production platform that competitors relying on single-isotope generator or external supplier arrangements cannot easily replicate quickly.
• Regulatory timing is a meaningful execution variable: cyclotron-produced gallium-68 and particularly technetium-99m face site-specific FDA approval requirements that could affect how quickly each installation becomes commercially productive.
• The theranostics industry is undergoing rapid vertical integration, with Novartis, Eli Lilly (via Point Biopharma), and Bristol Myers Squibb (via RayzeBio) all building or acquiring manufacturing infrastructure; Telix’s distributed radiopharmacy model is a structurally different approach with national coverage advantages.
• FY2026 is a proving year for Telix: US$950 to US$970 million in guided revenue alongside US$200 to US$240 million in pipeline R&D spend leaves limited buffer for manufacturing rollout delays or integration setbacks at RLS.